LLY

1,161.33

+2.09%↑

JNJ

232.92

+2.34%↑

ABBV

229.07

+3.07%↑

UNH

402.28

+1.69%↑

MRK

122.75

+3.13%↑

LLY

1,161.33

+2.09%↑

JNJ

232.92

+2.34%↑

ABBV

229.07

+3.07%↑

UNH

402.28

+1.69%↑

MRK

122.75

+3.13%↑

LLY

1,161.33

+2.09%↑

JNJ

232.92

+2.34%↑

ABBV

229.07

+3.07%↑

UNH

402.28

+1.69%↑

MRK

122.75

+3.13%↑

LLY

1,161.33

+2.09%↑

JNJ

232.92

+2.34%↑

ABBV

229.07

+3.07%↑

UNH

402.28

+1.69%↑

MRK

122.75

+3.13%↑

LLY

1,161.33

+2.09%↑

JNJ

232.92

+2.34%↑

ABBV

229.07

+3.07%↑

UNH

402.28

+1.69%↑

MRK

122.75

+3.13%↑

Accueil・Liste d'Actions・NeoGenomics Inc

NeoGenomics Inc

Ouvert

11.02 -4.09

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

10.99

Max

11.57

Chiffres clés
By Trading Economics
Revenu	-7.2M -17M
Ventes	-3.5M 187M
BPA	0.01
Marge bénéficiaire	-9.164
Employés	2,500
EBITDA	-5.8M -567K

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+32.01% upside

Dividendes
By Dow Jones
Prochains Résultats	28 juil. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	239M 1.4B
Ouverture précédente	15.11
Clôture précédente	11.02

NeoGenomics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 juin 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 juin 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 juin 2026, 09:20 UTC

Market Talk

Ether Stays Under Pressure, Underpeforming Bitcoin -- Market Talk

4 juin 2026, 07:23 UTC

Market Talk

Bitcoin Remains Weak on Geopolitical Uncertainty, U.S. Rate-Rise Bets -- Market Talk

4 juin 2026, 03:02 UTC

Market Talk

Bitcoin Slips Amid Risk-Off Sentiment -- Market Talk

3 juin 2026, 18:24 UTC

Market Talk

New Bitcoin Support Level at $65k -- Market Talk

3 juin 2026, 17:21 UTC

Market Talk

Long Liquidations in Bitcoin Mount -- Market Talk

3 juin 2026, 14:52 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 juin 2026, 14:52 UTC

Market Talk

Privacy Coins Gain Amid BTC Weakness -- Market Talk

3 juin 2026, 07:05 UTC

Market Talk

Bitcoin Falls After Fresh Attacks Between U.S. and Iran -- Market Talk

2 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2 juin 2026, 16:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 juin 2026, 16:25 UTC

Market Talk

Solana Plummets as Memecoin Appetite Fades -- Market Talk

2 juin 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

2 juin 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

2 juin 2026, 16:08 UTC

Market Talk

Global Equities Roundup: Market Talk

2 juin 2026, 16:08 UTC

Market Talk

Bitcoin Out of Top 10 Assets as Downturn Deepens -- Market Talk

2 juin 2026, 14:12 UTC

Market Talk

Fear in Control of Crypto Market -- Market Talk

2 juin 2026, 14:10 UTC

Market Talk

Bitcoin Tumbles Below $70k on ETF Outflow -- Market Talk

2 juin 2026, 11:25 UTC

Market Talk

Bitcoin Stays Weak on Geopolitical Uncertainty, Strategy's Sale of Cryptocurrency -- Market Talk

2 juin 2026, 07:17 UTC

Market Talk

Bitcoin Extends Losses on Strategy Sale, Middle East Conflict -- Market Talk

1 juin 2026, 16:54 UTC

Market Talk

Correction to Hyperliquid Market Talk

1 juin 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

1 juin 2026, 15:53 UTC

Market Talk

Hyperliquid Hits Record as ETFs Inflows Continue -- Market Talk

1 juin 2026, 15:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 juin 2026, 15:17 UTC

Market Talk

Late May Woes Look to Extend Into June for Crypto -- Market Talk

1 juin 2026, 14:47 UTC

Market Talk

Money in Bitcoin ETFs Keep Flowing Out -- Market Talk

1 juin 2026, 14:47 UTC

Market Talk

Global Equities Roundup: Market Talk

1 juin 2026, 14:42 UTC

Acquisitions, Fusions, Rachats

Strategy Sells Bitcoin for First Time Since 2022. The Stock Is Sliding. -- Barrons.com

1 juin 2026, 13:58 UTC

Market Talk

Bitcoin Hits 7-Week Low After Report of Iran Halting Talks -- Market Talk

Comparaison

Variation de prix

NeoGenomics Inc prévision

Objectif de Prix

By TipRanks

32.01% hausse

Prévisions sur 12 Mois

Moyen 14.93 USD 32.01%

Haut 25 USD

Bas 11 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

10 ratings

Achat

Maintien

Vente

Basé sur 10 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos NeoGenomics Inc

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.